Indexado en

Licencia y uso

Citaciones

Cited 16 times in

Cited 23 times in

Altmetrics

Grant support

We have no conflicts of interest that are directly relevant to the context of this study. This study was funded by a grant from the Spanish Health Department (Ministerio de Sanidad, Politica Social e Igualdad; EC10-093) and by the Lluita contra la SIDA Foundation, Gala contra la SIDA, Barcelona, 2011. M. V. is supported by FIS through grant CP04/00121 from the Spanish Health Department in collaboration with Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Barcelona, and she is a member of CIBERSAM (a research network funded by the Spanish Health Ministry, Instituto de Salud Carlos III).

Análisis de autorías institucional

Compartir

Herb-Drug Interaction between Echinacea purpurea and Etravirine in HIV-Infected Patients

Publicado en:Antimicrobial Agents And Chemotherapy. 56 (10): 5328-5331 - 2012-10-01 56(10), DOI: 10.1128/AAC.01205-12

Autores: Molto, Jose; Valle, Marta; Miranda, Cristina; Cedeno, Samandhy; Negredo, Eugenia; Clotet, Bonaventura

Afiliaciones

Resumen

The aim of this open-label, fixed-sequence study was to investigate the potential of the botanical supplement Echinacea purpurea to interact with etravirine, a nonnucleoside reverse transcriptase inhibitor of HIV. Fifteen HIV-infected patients receiving antiretroviral therapy with etravirine (400 mg once daily) for at least 4 weeks were included. E. purpurea root/extract-containing capsules were added to the antiretroviral treatment (500 mg every 8 h) for 14 days. Etravirine concentrations in plasma were determined by high-performance liquid chromatography immediately before and 1, 2, 4, 6, 8, 10, 12, and 24 h after a morning dose of etravirine on day 0 and etravirine plus E. purpurea on day 14. Individual etravirine pharmacokinetic parameters were calculated by noncompartmental analysis and compared between days 0 and 14 by means of the geometric mean ratio (GMR) and its 90% confidence interval (CI). The median age was 46 years (interquartile range, 41 to 50), and the median body weight was 76 kg (interquartile range, 68 to 92). Echinacea was well tolerated, and all participants completed the study. The GMR for etravirine coadministered with E. purpurea relative to etravirine alone was 1.07 (90% CI, 0.81 to 1.42) for the maximum concentration, 1.04 (90% CI, 0.79 to 1.38) for the area under the concentration-time curve from 0 to 24 h, and 1.04 (90% CI, 0.74 to 1.44) for the concentration at the end of the dosing interval. In conclusion, the coadministration of E. purpurea with etravirine was safe and well tolerated in HIV-infected patients; our data suggest that no dose adjustment for etravirine is necessary.

Palabras clave